Follow us

NANORAD-1: First-in-human phase 1b clinical trial on brain metastasis

;

Very favorable safety profile of AGuIX®
after intravenous injection

;

Demonstrated rapid renal elimination

=

Targeting evidence of metastasis by AGuIX®

=

Contrast enhancement visible in MRI after targeting

=

Dose-correlated uptake of AGuIX® in brain metastasis

nanorad-1
=

Efficient tumor volume reduction after radiation with AGuIX®
(clinical benefit for 13 patients/14)

=

Correlation between the dose of AGuIX® and the tumor volume reduction

This study has been the subject of two publications in peer-reviewed international journals

Verry et al., 2021 - Radiotherapy & Oncology

Theranostic AGuIX® nanoparticles as radiosensitizer: A phase I, dose-escalation study in patients with multiple brain metastases (NANO-RAD trial)

Verry et al., 2020 - Science Advances

Targeting brain metastases with ultrasmall theranostic nanoparticles, a first-in-human trial from an MRI perspective